Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seattle Genetics Inc.

www.seattlegenetics.com

Latest From Seattle Genetics Inc.

BerGenBio Adds Another Brick To AXL Inhibitor Bemcentinib’s AML Potential

As the most advanced AXL inhibitor product in the global pipeline, BerGenBio’s bemcentinib has continued to show encouraging data in AML, following on from monotherapy trials last year.

Cancer Research & Development

Asia Deal Watch: Takeda On A Deal Spree

Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.

Asia Pacific Commercial

Enfortumab Vedotin Impresses In Urothelial Cancer After Chemo, Immunotherapies

The antibody-drug conjugate being evaluated by Astellas and Seattle Genetics has posted “remarkable” positive top-line results in locally advanced or metastatic urothelial cancer, with a US BLA submission expected later in 2019.

 

Cancer Clinical Trials

Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Approvals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register